Melinta Therapeutics (MLNT) Stock Price Up 12.2% on Earnings Beat

Melinta Therapeutics, Inc. (NASDAQ:MLNT) shares rose 12.2% during trading on Thursday following a better than expected earnings announcement. The stock traded as high as $2.88 and last traded at $2.86. Approximately 561,654 shares traded hands during mid-day trading, an increase of 61% from the average daily volume of 348,264 shares. The stock had previously closed at $2.55.

The biotechnology company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.55. The business had revenue of $34.08 million during the quarter, compared to the consensus estimate of $17.24 million. Melinta Therapeutics had a negative net margin of 348.51% and a negative return on equity of 67.60%.

Several analysts have recently commented on the stock. Gabelli raised shares of Melinta Therapeutics from a “hold” rating to a “buy” rating and set a $11.50 price objective for the company in a research report on Monday, October 22nd. They noted that the move was a valuation call. HC Wainwright reduced their price objective on shares of Melinta Therapeutics from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Monday, October 22nd. ValuEngine raised shares of Melinta Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd. Zacks Investment Research downgraded shares of Melinta Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 13th. Finally, Jefferies Financial Group assumed coverage on shares of Melinta Therapeutics in a research report on Tuesday, September 11th. They set a “buy” rating and a $15.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $10.75.

Several hedge funds have recently made changes to their positions in MLNT. Northern Trust Corp grew its position in shares of Melinta Therapeutics by 48.0% during the 1st quarter. Northern Trust Corp now owns 166,112 shares of the biotechnology company’s stock worth $1,229,000 after buying an additional 53,889 shares during the period. BlackRock Inc. lifted its holdings in shares of Melinta Therapeutics by 41.8% in the 1st quarter. BlackRock Inc. now owns 857,398 shares of the biotechnology company’s stock worth $6,344,000 after purchasing an additional 252,943 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Melinta Therapeutics by 10.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 476,212 shares of the biotechnology company’s stock worth $3,524,000 after purchasing an additional 45,784 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of Melinta Therapeutics by 48.5% in the 1st quarter. California State Teachers Retirement System now owns 23,035 shares of the biotechnology company’s stock worth $170,000 after purchasing an additional 7,520 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Melinta Therapeutics by 60.2% in the 1st quarter. Millennium Management LLC now owns 446,713 shares of the biotechnology company’s stock worth $3,306,000 after purchasing an additional 167,798 shares in the last quarter. 69.40% of the stock is owned by institutional investors.

The company has a debt-to-equity ratio of 0.41, a current ratio of 1.97 and a quick ratio of 1.65. The firm has a market capitalization of $148.99 million, a PE ratio of -0.13 and a beta of 1.45.

TRADEMARK VIOLATION NOTICE: This piece was first posted by WKRB News and is the sole property of of WKRB News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.wkrb13.com/2018/11/08/melinta-therapeutics-mlnt-stock-price-up-12-2-on-earnings-beat.html.

About Melinta Therapeutics (NASDAQ:MLNT)

Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP.

Further Reading: How can you know how many shares are floating?

Receive News & Ratings for Melinta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Melinta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply